×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 3: Point to Consider on CMC Comparability Challenges Through the Development of the Gene Therapy Products [English]
Session Chair(s)
Kazunobu Oyama, PhD
Daiichi Sankyo Company, Limited, Japan
Mika Yoshimatsu
Manager, CMC Planning Department
Janssen Pharmaceutical K.K., Japan
Speaker(s)
Jaclyn Moxham
Pfizer , United States
Niamh Kinsella
Biogen, United Kingdom
Associate Director, Global Regulatory CMC Early Development Gene Therapy Lead
Alison Armstrong
Merck BioReliance, United Kingdom
Global Head of Field Technology Management
Have an account?